Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report
- 4 April 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular Oncology
- Vol. 39 (3), 287-293
- https://doi.org/10.1007/s13402-016-0279-3
Abstract
Purpose CYLD is a tumor suppressor that has been linked to the development of various human malignancies, including colon cancer. The tumor-suppressing function of CYLD is associated with its deubiquitinating activity, which maps to the carboxyl-terminal region of the protein. In the present study we evaluated the role of intestinal epithelial CYLD in colitis-associated cancer using a conditional mouse CYLD inactivation model. Methods In order to evaluate the role of CYLD in intestinal epithelial carcinogenesis, mice (IEC-Cyld Δ9 mice) that carry a mutation that eliminates the deubiquitinating domain of CYLD in intestinal epithelial cells (IEC) were generated by crossing Villin-Cre transgenic mice to previously generated mice carrying a loxP-flanked Cyld exon 9 (Cyld flx9 mice). Results We found that IEC-Cyld Δ9 mice did not present spontaneous intestinal abnormalities up to one year of age. However, upon challenge with a combination of genotoxic (AOM) and pro-inflammatory (DSS) agents we found that the number of adenomas in the IEC-Cyld Δ9 mice was dramatically increased compared to the control mice. Inactivation of CYLD in intestinal epithelial cells did not affect the classical nuclear factor-kappaB (NF-κB) and c-Jun kinase (JNK) activation pathways under physiological conditions, suggesting that these pathways do not predispose CYLD-deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and/or pro-inflammatory stress. Conclusions Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis. CYLD expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.Keywords
Funding Information
- Aristotle University of Thessaloniki (GR)
- Hellenic State Scholarships foundation
This publication has 27 references indexed in Scilit:
- NF-κB signaling in cancer stem cells: a promising therapeutic target?Cellular Oncology, 2015
- Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel diseaseGut, 2013
- Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2013
- FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammationNature, 2011
- CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processesCell Death & Differentiation, 2009
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Reduced expression of CYLD in human colon and hepatocellular carcinomasCarcinogenesis: Integrative Cancer Research, 2007
- Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA MicroarraysPLoS Medicine, 2005
- Identification of the familial cylindromatosis tumour-suppressor geneNature Genetics, 2000